Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Preface.

Sinz M.

Curr Drug Metab. 2019;20(1):2. doi: 10.2174/138920022001190125110659. No abstract available.

PMID:
30887914
2.

Identification of novel glutathione conjugates of terbinafine in liver microsomes and hepatocytes across species.

Patil A, Ladumor MK, Kamble SH, Johnson BM, Subramanian M, Sinz MW, Singh DK, Putlur S, Bhutani P, Ahire DS, Singh S.

Xenobiotica. 2019 Feb 12:1-11. doi: 10.1080/00498254.2019.1581959. [Epub ahead of print]

PMID:
30747549
3.

BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder.

Marcin LR, Warrier J, Thangathirupathy S, Shi J, Karageorge GN, Pearce BC, Ng A, Park H, Kempson J, Li J, Zhang H, Mathur A, Reddy AB, Nagaraju G, Tonukunuru G, Gupta GVRKM, Kamble M, Mannoori R, Cheruku S, Jogi S, Gulia J, Bastia T, Sanmathi C, Aher J, Kallem R, Srikumar BN, Vijaya KK, Naidu PS, Paschapur M, Kalidindi N, Vikramadithyan R, Ramarao M, Denton R, Molski T, Shields E, Subramanian M, Zhuo X, Nophsker M, Simmermacher J, Sinz M, Albright C, Bristow LJ, Islam I, Bronson JJ, Olson RE, King D, Thompson LA, Macor JE.

ACS Med Chem Lett. 2018 Apr 13;9(5):472-477. doi: 10.1021/acsmedchemlett.8b00080. eCollection 2018 May 10.

PMID:
29795762
4.

Evaluation of Farnesoid X Receptor Target Gene Induction in Human Hepatocytes: Amino Acid Conjugation.

Simmermacher J, Sinz M.

Drug Metab Lett. 2017;11(2):138-143. doi: 10.2174/1872312812666171227213946.

PMID:
29283075
5.

Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder.

Bristow LJ, Gulia J, Weed MR, Srikumar BN, Li YW, Graef JD, Naidu PS, Sanmathi C, Aher J, Bastia T, Paschapur M, Kalidindi N, Kumar KV, Molski T, Pieschl R, Fernandes A, Brown JM, Sivarao DV, Newberry K, Bookbinder M, Polino J, Keavy D, Newton A, Shields E, Simmermacher J, Kempson J, Li J, Zhang H, Mathur A, Kallem RR, Sinha M, Ramarao M, Vikramadithyan RK, Thangathirupathy S, Warrier J, Islam I, Bronson JJ, Olson RE, Macor JE, Albright CF, King D, Thompson LA, Marcin LR, Sinz M.

J Pharmacol Exp Ther. 2017 Dec;363(3):377-393. doi: 10.1124/jpet.117.242784. Epub 2017 Sep 27.

PMID:
28954811
6.

Preface.

Sinz MW.

Curr Drug Metab. 2017;18(1):1. doi: 10.2174/138920021801170119202545. No abstract available.

PMID:
28889795
7.

Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidance from Regulatory Agencies: Focus on Downregulation, CYP2C Induction, and CYP2B6 Positive Control.

Hariparsad N, Ramsden D, Palamanda J, Dekeyser JG, Fahmi OA, Kenny JR, Einolf H, Mohutsky M, Pardon M, Siu YA, Chen L, Sinz M, Jones B, Walsky R, Dallas S, Balani SK, Zhang G, Buckley D, Tweedie D.

Drug Metab Dispos. 2017 Oct;45(10):1049-1059. doi: 10.1124/dmd.116.074567. Epub 2017 Jun 23.

PMID:
28646080
8.

Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies.

Yeung KS, Beno BR, Parcella K, Bender JA, Grant-Young KA, Nickel A, Gunaga P, Anjanappa P, Bora RO, Selvakumar K, Rigat K, Wang YK, Liu M, Lemm J, Mosure K, Sheriff S, Wan C, Witmer M, Kish K, Hanumegowda U, Zhuo X, Shu YZ, Parker D, Haskell R, Ng A, Gao Q, Colston E, Raybon J, Grasela DM, Santone K, Gao M, Meanwell NA, Sinz M, Soars MG, Knipe JO, Roberts SB, Kadow JF.

J Med Chem. 2017 May 25;60(10):4369-4385. doi: 10.1021/acs.jmedchem.7b00328. Epub 2017 May 4.

PMID:
28430437
9.

A Novel Liquid Chromatography Tandem Mass Spectrometry Method for the Estimation of Bilirubin Glucuronides and its Application to In Vitro Enzyme Assays.

Putluru SP, Matta MK, Ahire D, Subramanian M, Sinz M, Mandlekar S.

Drug Metab Lett. 2017;10(4):264-269. doi: 10.2174/1872312810666161124143522.

PMID:
27908259
10.

Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.

Sun LQ, Mull E, Zheng B, D'Andrea S, Zhao Q, Wang AX, Sin N, Venables BL, Sit SY, Chen Y, Chen J, Cocuzza A, Bilder DM, Mathur A, Rampulla R, Chen BC, Palani T, Ganesan S, Arunachalam PN, Falk P, Levine S, Chen C, Friborg J, Yu F, Hernandez D, Sheaffer AK, Knipe JO, Han YH, Schartman R, Donoso M, Mosure K, Sinz MW, Zvyaga T, Rajamani R, Kish K, Tredup J, Klei HE, Gao Q, Ng A, Mueller L, Grasela DM, Adams S, Loy J, Levesque PC, Sun H, Shi H, Sun L, Warner W, Li D, Zhu J, Wang YK, Fang H, Cockett MI, Meanwell NA, McPhee F, Scola PM.

J Med Chem. 2016 Sep 8;59(17):8042-60. doi: 10.1021/acs.jmedchem.6b00821. Epub 2016 Aug 26.

PMID:
27564532
11.

Evaluation of CYP2B6 Induction and Prediction of Clinical Drug-Drug Interactions: Considerations from the IQ Consortium Induction Working Group-An Industry Perspective.

Fahmi OA, Shebley M, Palamanda J, Sinz MW, Ramsden D, Einolf HJ, Chen L, Wang H.

Drug Metab Dispos. 2016 Oct;44(10):1720-30. doi: 10.1124/dmd.116.071076. Epub 2016 Jul 15.

PMID:
27422672
12.

Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.

Bohnert T, Patel A, Templeton I, Chen Y, Lu C, Lai G, Leung L, Tse S, Einolf HJ, Wang YH, Sinz M, Stearns R, Walsky R, Geng W, Sudsakorn S, Moore D, He L, Wahlstrom J, Keirns J, Narayanan R, Lang D, Yang X; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Victim Drug-Drug Interactions Working Group.

Drug Metab Dispos. 2016 Aug;44(8):1399-423. doi: 10.1124/dmd.115.069096. Epub 2016 Apr 6. Review.

PMID:
27052879
13.

Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.

Mosure KW, Knipe JO, Browning M, Arora V, Shu YZ, Phillip T, Mcphee F, Scola P, Balakrishnan A, Soars MG, Santone K, Sinz M.

J Pharm Sci. 2015 Sep;104(9):2813-23. doi: 10.1002/jps.24356. Epub 2015 Jan 28.

PMID:
25631585
14.

Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.

Liu S, Zha C, Nacro K, Hu M, Cui W, Yang YL, Bhatt U, Sambandam A, Isherwood M, Yet L, Herr MT, Ebeltoft S, Hassler C, Fleming L, Pechulis AD, Payen-Fornicola A, Holman N, Milanowski D, Cotterill I, Mozhaev V, Khmelnitsky Y, Guzzo PR, Sargent BJ, Molino BF, Olson R, King D, Lelas S, Li YW, Johnson K, Molski T, Orie A, Ng A, Haskell R, Clarke W, Bertekap R, O'Connell J, Lodge N, Sinz M, Adams S, Zaczek R, Macor JE.

ACS Med Chem Lett. 2014 May 13;5(7):760-5. doi: 10.1021/ml500053b. eCollection 2014 Jul 10.

15.

Preclinical pharmacokinetics and in vitro metabolism of BMS-605339: a novel HCV NS3 protease inhibitor.

Jenkins S, Scola P, McPhee F, Knipe J, Gesenberg C, Sinz M, Arora V, Pilcher G, Santone K.

J Pharm Sci. 2014 Jun;103(6):1891-902. doi: 10.1002/jps.23959. Epub 2014 Apr 3.

PMID:
24700293
16.

The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.

Scola PM, Sun LQ, Wang AX, Chen J, Sin N, Venables BL, Sit SY, Chen Y, Cocuzza A, Bilder DM, D'Andrea SV, Zheng B, Hewawasam P, Tu Y, Friborg J, Falk P, Hernandez D, Levine S, Chen C, Yu F, Sheaffer AK, Zhai G, Barry D, Knipe JO, Han YH, Schartman R, Donoso M, Mosure K, Sinz MW, Zvyaga T, Good AC, Rajamani R, Kish K, Tredup J, Klei HE, Gao Q, Mueller L, Colonno RJ, Grasela DM, Adams SP, Loy J, Levesque PC, Sun H, Shi H, Sun L, Warner W, Li D, Zhu J, Meanwell NA, McPhee F.

J Med Chem. 2014 Mar 13;57(5):1730-52. doi: 10.1021/jm500297k. Epub 2014 Mar 5.

PMID:
24564672
17.

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

Scola PM, Wang AX, Good AC, Sun LQ, Combrink KD, Campbell JA, Chen J, Tu Y, Sin N, Venables BL, Sit SY, Chen Y, Cocuzza A, Bilder DM, D'Andrea S, Zheng B, Hewawasam P, Ding M, Thuring J, Li J, Hernandez D, Yu F, Falk P, Zhai G, Sheaffer AK, Chen C, Lee MS, Barry D, Knipe JO, Li W, Han YH, Jenkins S, Gesenberg C, Gao Q, Sinz MW, Santone KS, Zvyaga T, Rajamani R, Klei HE, Colonno RJ, Grasela DM, Hughes E, Chien C, Adams S, Levesque PC, Li D, Zhu J, Meanwell NA, McPhee F.

J Med Chem. 2014 Mar 13;57(5):1708-29. doi: 10.1021/jm401840s. Epub 2014 Feb 20.

PMID:
24555570
18.

Expression and characterization of cynomolgus monkey cytochrome CYP3A4 in a novel human embryonic kidney cell-based mammalian system.

Selvakumar S, Bhutani P, Ghosh K, Krishnamurthy P, Kallipatti S, Selvam S, Ramarao M, Mandlekar S, Sinz MW, Rodrigues AD, Subramanian M.

Drug Metab Dispos. 2014 Mar;42(3):369-76. doi: 10.1124/dmd.113.055491. Epub 2013 Dec 13.

PMID:
24335510
19.

Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data.

Einolf HJ, Chen L, Fahmi OA, Gibson CR, Obach RS, Shebley M, Silva J, Sinz MW, Unadkat JD, Zhang L, Zhao P.

Clin Pharmacol Ther. 2014 Feb;95(2):179-88. doi: 10.1038/clpt.2013.170. Epub 2013 Aug 29.

PMID:
23995268
20.

Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone.

Hassan HE, Myers AL, Lee IJ, Mason CW, Wang D, Sinz MW, Wang H, Eddington ND.

Drug Metab Dispos. 2013 May;41(5):1060-9. doi: 10.1124/dmd.112.050401. Epub 2013 Feb 25.

PMID:
23439660
21.

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 13. Synthesis and profiling of a novel amminium prodrug of the HIV-1 attachment inhibitor BMS-585248.

Regueiro-Ren A, Simmermacher-Mayer J, Sinz M, Johnson KA, Huang XS, Jenkins S, Parker D, Rahematpura S, Zheng M, Meanwell NA, Kadow JF.

J Med Chem. 2013 Feb 28;56(4):1670-6. doi: 10.1021/jm301638a. Epub 2013 Feb 12.

PMID:
23374053
22.

Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development.

Sinz MW.

Drug Metab Rev. 2013 Feb;45(1):3-14. doi: 10.3109/03602532.2012.743560. Review.

PMID:
23330538
23.

A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.

Kallem R, Kulkarni CP, Patel D, Thakur M, Sinz M, Singh SP, Mahammad SS, Mandlekar S.

Drug Metab Lett. 2012 Jun 1;6(2):134-44.

PMID:
23061481
24.

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).

McPhee F, Sheaffer AK, Friborg J, Hernandez D, Falk P, Zhai G, Levine S, Chaniewski S, Yu F, Barry D, Chen C, Lee MS, Mosure K, Sun LQ, Sinz M, Meanwell NA, Colonno RJ, Knipe J, Scola P.

Antimicrob Agents Chemother. 2012 Oct;56(10):5387-96. doi: 10.1128/AAC.01186-12. Epub 2012 Aug 6.

25.

An insulin-like growth factor 1 receptor inhibitor induces CYP3A4 expression through a pregnane X receptor-independent, noncanonical constitutive androstane receptor-related mechanism.

Li L, Sinz MW, Zimmermann K, Wang H.

J Pharmacol Exp Ther. 2012 Mar;340(3):688-97. doi: 10.1124/jpet.111.188854. Epub 2011 Dec 9.

26.

Phenacetin pharmacokinetics in CYP1A2-deficient beagle dogs.

Whiterock VJ, Morgan DG, Lentz KA, Orcutt TL, Sinz MW.

Drug Metab Dispos. 2012 Feb;40(2):228-31. doi: 10.1124/dmd.111.041848. Epub 2011 Nov 10.

PMID:
22074769
27.

Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers.

Gerritz SW, Cianci C, Kim S, Pearce BC, Deminie C, Discotto L, McAuliffe B, Minassian BF, Shi S, Zhu S, Zhai W, Pendri A, Li G, Poss MA, Edavettal S, McDonnell PA, Lewis HA, Maskos K, Mörtl M, Kiefersauer R, Steinbacher S, Baldwin ET, Metzler W, Bryson J, Healy MD, Philip T, Zoeckler M, Schartman R, Sinz M, Leyva-Grado VH, Hoffmann HH, Langley DR, Meanwell NA, Krystal M.

Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15366-71. doi: 10.1073/pnas.1107906108. Epub 2011 Sep 6.

28.

Pharmacokinetic-pharmacodynamic modeling of rifampicin-mediated Cyp3a11 induction in steroid and xenobiotic X receptor humanized mice.

Raybon JJ, Pray D, Morgan DG, Zoeckler M, Zheng M, Sinz M, Kim S.

J Pharmacol Exp Ther. 2011 Apr;337(1):75-82. doi: 10.1124/jpet.110.176677. Epub 2010 Dec 27.

PMID:
21205914
29.

SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.

Zimmermann K, Wittman MD, Saulnier MG, Velaparthi U, Sang X, Frennesson DB, Struzynski C, Seitz SP, He L, Carboni JM, Li A, Greer AF, Gottardis M, Attar RM, Yang Z, Balimane P, Discenza LN, Lee FY, Sinz M, Kim S, Vyas D.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1744-8. doi: 10.1016/j.bmcl.2010.01.087. Epub 2010 Jan 21.

PMID:
20153189
30.

Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction.

Kim S, Dinchuk JE, Anthony MN, Orcutt T, Zoeckler ME, Sauer MB, Mosure KW, Vuppugalla R, Grace JE Jr, Simmermacher J, Dulac HA, Pizzano J, Sinz M.

Drug Metab Dispos. 2010 Jan;38(1):16-24. doi: 10.1124/dmd.109.029637.

PMID:
19833845
31.

In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective.

Chu V, Einolf HJ, Evers R, Kumar G, Moore D, Ripp S, Silva J, Sinha V, Sinz M, Skerjanec A.

Drug Metab Dispos. 2009 Jul;37(7):1339-54. doi: 10.1124/dmd.109.027029. Epub 2009 Apr 23.

PMID:
19389860
32.

Quantitative relationship between rifampicin exposure and induction of Cyp3a11 in SXR humanized mice: extrapolation to human CYP3A4 induction potential.

Kim S, Pray D, Zheng M, Morgan DG, Pizzano JG, Zoeckler ME, Chimalakonda A, Sinz MW.

Drug Metab Lett. 2008 Aug;2(3):169-75.

PMID:
19356089
33.

Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer.

Gupta D, Venkatesh M, Wang H, Kim S, Sinz M, Goldberg GL, Whitney K, Longley C, Mani S.

Clin Cancer Res. 2008 Sep 1;14(17):5332-40. doi: 10.1158/1078-0432.CCR-08-1033.

34.

Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.

Velaparthi U, Wittman M, Liu P, Carboni JM, Lee FY, Attar R, Balimane P, Clarke W, Sinz MW, Hurlburt W, Patel K, Discenza L, Kim S, Gottardis M, Greer A, Li A, Saulnier M, Yang Z, Zimmermann K, Trainor G, Vyas D.

J Med Chem. 2008 Oct 9;51(19):5897-900. doi: 10.1021/jm800832q. Epub 2008 Sep 3.

PMID:
18763755
35.

Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical.

Sinz M, Wallace G, Sahi J.

AAPS J. 2008 Jun;10(2):391-400. doi: 10.1208/s12248-008-9037-4. Epub 2008 Aug 7. Review.

36.

Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR).

Das BC, Madhukumar AV, Anguiano J, Kim S, Sinz M, Zvyaga TA, Power EC, Ganellin CR, Mani S.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):3974-7. doi: 10.1016/j.bmcl.2008.06.018. Epub 2008 Jun 10.

PMID:
18583127
37.

Computational discovery of novel low micromolar human pregnane X receptor antagonists.

Ekins S, Kholodovych V, Ai N, Sinz M, Gal J, Gera L, Welsh WJ, Bachmann K, Mani S.

Mol Pharmacol. 2008 Sep;74(3):662-72. doi: 10.1124/mol.108.049437. Epub 2008 Jun 25.

PMID:
18579710
38.

Machine learning methods and docking for predicting human pregnane X receptor activation.

Khandelwal A, Krasowski MD, Reschly EJ, Sinz MW, Swaan PW, Ekins S.

Chem Res Toxicol. 2008 Jul;21(7):1457-67. doi: 10.1021/tx800102e. Epub 2008 Jun 12.

39.

Cytochrome P450 reaction-phenotyping: an industrial perspective.

Zhang H, Davis CD, Sinz MW, Rodrigues AD.

Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):667-87. Review.

PMID:
17916054
40.

Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites.

Ekins S, Chang C, Mani S, Krasowski MD, Reschly EJ, Iyer M, Kholodovych V, Ai N, Welsh WJ, Sinz M, Swaan PW, Patel R, Bachmann K.

Mol Pharmacol. 2007 Sep;72(3):592-603. Epub 2007 Jun 18.

PMID:
17576789
41.

Activated pregnenolone X-receptor is a target for ketoconazole and its analogs.

Wang H, Huang H, Li H, Teotico DG, Sinz M, Baker SD, Staudinger J, Kalpana G, Redinbo MR, Mani S.

Clin Cancer Res. 2007 Apr 15;13(8):2488-95.

42.

Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.

Yao M, Zhu M, Sinz MW, Zhang H, Humphreys WG, Rodrigues AD, Dai R.

J Pharm Biomed Anal. 2007 May 9;44(1):211-23. Epub 2007 Mar 3.

PMID:
17418993
43.

Frequency of CYP1A2 polymorphism in beagle dogs.

Whiterock VJ, Delmonte TA, Hui LE, Orcutt TL, Sinz MW.

Drug Metab Lett. 2007 Apr;1(2):163-5.

PMID:
19356037
44.

The utility of stable cell lines to assess species differences in PXR transactivation.

Sinz MW, Pray D, Raucy J.

Drug Metab Lett. 2007 Apr;1(2):147-52.

PMID:
19356035
45.

Use of cryopreserved transiently transfected cells in high-throughput pregnane X receptor transactivation assay.

Zhu Z, Puglisi J, Connors D, Stewart J, Herbst J, Marino A, Sinz M, O'Connell J, Banks M, Dickinson K, Cacace A.

J Biomol Screen. 2007 Mar;12(2):248-54. Epub 2007 Jan 26.

PMID:
17259590
46.

Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, Sinz M, Rodrigues AD.

Clin Pharmacokinet. 2007;46(2):133-57. Review.

PMID:
17253885
47.

Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele?

Rodrigues AD, Yang Z, Chen C, Pray D, Kim S, Sinz M.

Clin Pharmacol Ther. 2006 Sep;80(3):298-301; author reply 301-02. No abstract available.

PMID:
16952496
48.

Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole.

Huang H, Wang H, Sinz M, Zoeckler M, Staudinger J, Redinbo MR, Teotico DG, Locker J, Kalpana GV, Mani S.

Oncogene. 2007 Jan 11;26(2):258-68. Epub 2006 Jul 3.

PMID:
16819505
49.

Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions.

Sinz M, Kim S, Zhu Z, Chen T, Anthony M, Dickinson K, Rodrigues AD.

Curr Drug Metab. 2006 May;7(4):375-88.

PMID:
16724927
50.

Stem cells, immortalized cells and primary cells in ADMET assays.

Sinz MW, Kim S.

Drug Discov Today Technol. 2006 Spring;3(1):79-85. doi: 10.1016/j.ddtec.2006.03.006.

PMID:
24980105

Supplemental Content

Support Center